Bo-lin Zhang

[Differences between clinical response and pathologic response of breast cancer after neoadjuvant chemotherapy].

L. Xue, S. Zou, Ren-zhi Zhang, 2010, Zhonghua bing li xue za zhi = Chinese journal of pathology.

Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma.

Xin Zhang, Jing Huang, L. Qi, 2019, Journal of Clinical Oncology.

Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study.

Y. Shu, Qun Li, Jing Huang, 2020 .